News
While patients with psoriasis — a chronic skin condition — respond well to treatment with biologics, inflammation can linger, ...
17h
Clinical Trials Arena on MSNAccropeutics’ TYK2/JAK1 inhibitor meets endpoints in Phase II psoriasis trialAccropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...
Let’s discuss four foods to avoid with psoriasis that may be affecting your skin, along with healthier substitutes.
Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...
Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...
17h
HealthDay on MSNResidual Inflammation Seen in One-Third of Patients With Psoriasis on BiologicsFor patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...
Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.
A new study published in the journal of Acta Dermato Venerologica showed that menopause might have neutral to negative impact ...
Learn to distinguish between nail psoriasis and nail fungus through key visual differences, associated symptoms, and ...
Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...
How does one live with psoriasis? From medication to nutrition (and beyond), Olivia Marks goes in search of clear answers.
Researchers reviewed a host of studies investigating diet plans in an effort to guide evidence-based recommendations for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results